Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
The developer of eye drugs has yet to launch a product on the market and could face financial pressure if its latest listing attempt falters Key Takeaways: Cloudbreak has sold…
RELATED ARTICLES
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- TransThera seeks Hong Kong IPO to sustain cancer drug research
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
Discover hidden China stock gems in our weekly newsletter